ARCHIMED announces the close of its acquisition of Esperion Therapeutics, Inc. (formerly, NASDAQ: ESPR) (“Esperion”), a biopharmaceutical company bringing innovative cardiometabolic and rare/orphan disease therapies to market. The transaction is valued at up to approximately $1.1 billion (€962 million) in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones. Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion is a commercial-stage biopharmaceutical company that initially built its business on cutting-edge non-statin bempedoic acid-based drugs. Esperion reported net revenue of $403 million in 2025.
Read the full article: ARCHIMED Successfully Completes Take-Private of Esperion Therapeutics //
Source: https://www.archimed.group/news/archimed-successfully-completes-take-private-of-esperion/